investigational new drug safety reporting requirements (10of14) redi 2018
Published 4 years ago • 3.2K plays • Length 36:51Download video MP4
Download video MP3
Similar videos
-
33:18
investigational new drug (ind) submission: content/format and first 30 days (5of14) redi 2018
-
21:20
investigator responsibilities - safety reporting for investigational drugs and devices
-
46:00
introduction to investigational new drug (ind) applications (3/14) redi 2017
-
35:16
overview of postmarketing drug safety reporting requirements - redi 2020
-
35:38
safety reporting requirements and safety assessment for ind and ba/be studies
-
41:00
fda regulatory requirements for clinical investigators and case examples (9of14) redi 2018
-
40:34
demystifying the investigational new drug (ind) application for drugs and biologics (3of14) redi '18
-
27:21
digital ind safety reporting - pharmacovigilance 2020
-
1:00:11
human factors engineering in medical products reviews (2of14) redi 2018
-
48:21
fda adverse event reporting system (faers) overview - pharmacovigilance 2020
-
54:28
overview of non-clinical assessment in drug development (8/14) redi 2017
-
5:15
expanded access part 4: how to complete form fda 3926 for follow-up submissions
-
36:40
fda webinar on the infant formula food ingredients requirements
-
1:48:00
clinical investigator training course (citc) update - operational updates part 1
-
18:22
electronic submissions (7of27) generic drugs forum 2018
-
8:24:45
regulatory education for industry (redi) annual conference 2022 - day 5
-
24:08
premarket review of expedited serious adverse event reports of ba/be studies
-
1:10:23
fda clinical investigator training course (citc) 2022, day 1 – part 3
-
36:55
components of new drug application and biologics license application (5of15) redi– may 29-30, 2019